Tropifexor
Tropifexor is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target bile acid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 4 | — | — | — | 5 |
Biliary liver cirrhosis | D008105 | K74.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TROPIFEXOR |
INN | tropifexor |
Description | Tropifexor is an investigational drug that acts as an agonist of the farnesoid X receptor (FXR). It was discovered by researchers from Novartis and Genomics Institute of the Novartis Research Foundation. Its synthesis and pharmacological properties were published in 2017. It was developed for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). In combination with cenicriviroc, a CCR2 and CCR5 receptor inhibitor, it is undergoing a phase II clinical trial for NASH and liver fibrosis.
|
Classification | Small molecule |
Drug class | atropine derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1cc(F)c2nc(N3[C@H]4CC[C@@H]3C[C@H](OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1 |
Identifiers
PDB | — |
CAS-ID | 1383816-29-2 |
RxCUI | — |
ChEMBL ID | CHEMBL4298169 |
ChEBI ID | — |
PubChem CID | 121418176 |
DrugBank | DB16343 |
UNII ID | NMZ08KM76Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR1H4
NR1H4
Organism
Homo sapiens
Gene name
NR1H4
Gene synonyms
BAR, FXR, HRR1, RIP14
NCBI Gene ID
Protein name
bile acid receptor
Protein synonyms
farnesoid X nuclear receptor, Farnesoid X-activated receptor, Farnesol receptor HRR-1, Nuclear receptor subfamily 1 group H member 4, Retinoid X receptor-interacting protein 14, RXR-interacting protein 14
Uniprot ID
Mouse ortholog
Nr1h4 (20186)
bile acid receptor (Q60641)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 262 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more